In the News

Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24

Aulos Bioscience CEO Aron Knickerbocker discusses his company’s antibody approach to IL-2 at #ASCO24

June 2, 2024

CEO Aron Knickerbocker joins BiotechTV’s Brad Loncar to discuss the benefits of focusing on the CD25 binding portion of IL-2 as well as the data presented at ASCO.

Clinical Trials Arena

Aulos to begin Phase II portion of solid tumour therapy trial

December 19, 2023

With Aulos announcing the Phase 2 portion of its Phase 1/2 study of AU-007, Clinical Trials Arena summarizes AU-007 developments to date and notes what’s ahead with the Phase 2 expansion cohorts.

The Bio Report

Realizing the Promise of IL-2 Therapies with AI

December 13, 2023

CEO Aron Knickerbocker joins biotech insider Daniel Levine for an in-depth discussion on the potential for IL-2 therapies in solid tumors, how AU-007 differs from other drugs in the class and its AI-based design.

Targeted Oncology

Early Antitumor Activity and Safety Seen With AU-007 Across Solid Tumors

November 10, 2023

Targeted Oncology reports on AU-007 Phase 1 data presented at the 38th SITC Annual Meeting, with the drug showing early evidence of antitumor activity when given alone or in combination with aldesleukin.

BioWorld 082123 Aulos Bioscience Thumbnail

Aulos Bioscience raises $20 million in series A to further alternative IL-2 approach

August 21, 2023 | PDF 49KB

CEO Aron Knickerbocker speaks with BioWorld about the company’s $20 million Series A extension funding, the science behind AU-007 and the latest on its Phase 1/2 clinical study in solid tumor cancers.

LSL Leading Aulos Bioscience’s “Triumvirate” Model Thumbnail
Life Science Leader

Leading Aulos Bioscience’s “Triumvirate” Model

June 1, 2023

During an interview with Life Science Leader, CEO Aron Knickerbocker discusses Aulos’ commitment to maximizing the ingenuity of a balanced team and continuing development of AU-007, the company’s lead candidate.

Dolgin-2022-Nature_Biotechnology Thumbnail
Nature Biotechnology

IL-2 upgrades show promise at ASCO

July 13, 2022

Nature Biotechnology looks at IL-2 therapeutics, including AU-007 and its unique ability to bind to IL-2, blocking activation of trimeric receptors on Tregs and endothelial cells while stimulating effector T cells and NK cells.